Phantom ActivCore Hindfoot Nail System Launches

Today Paragon® 28 announced the launch of Phantom ActivCore Hindfoot Nail System. The Precision® Guided ActivCore Nail addresses a TTC arthrodesis and is the second of four hindfoot fusion nailing systems Paragon 28 plans to launch in 2020.

Phantom ActivCore Hindfoot Nail System is constructed from Type II Anodized Titanium Alloy and has an outer sheath with a proximal Flex Coil tip and inner sliding core which allows for constant active compression. The Nail is designed to maintain compression across all joint surfaces and can compensate for up to 8 mm of bone resorption. The Nail accommodates two Ø7.2 mm fully threaded, headless calcaneal Pegs that are inserted from posterior to anterior at a variable (0-18°) angle. These Pegs provide fixation distally and work with the inner core, outer sheath, and Tibial Pegs to allow for active compression to pass through the joint surfaces.

The ActivCore system leverages PRECISION® Guide technology allowing for reproducibility when placing a Ø3.0 mm Drill-pin from distal to proximal, through the center of the calcaneus and up to the tibia. As with the previous Phantom® Hindfoot Nail System, all ActivCore Nails are engineered with a proximal Flex Coil design to provide flexibility as the implant finds its way through the contouring of the tibial canal. All Pegs are inserted from posterior to anterior and medial to lateral eliminating the need to take down the fibula.

The Phantom® ActivCore Nails will be offered in 22 size options with three diameters and four lengths. The distal diameter of all Nails is Ø13.3 mm with a transition to either Ø10.0, Ø11.5 or Ø13.0 mm above the ankle joint and 10.0mm at the Flex Coil tip. The distal diameter was increased at the joint spaces to add strength to the implant where it is needed most. The Phantom® ActivCore System will include a comprehensive offering of procedural instrumentation to address joint preparation and restoration of anatomic alignment.

The ActivCore Nail is implanted utilizing the carbon fiber Phantom® Ghost™ Outrigger. The radiolucent and inlay features of the Outrigger allow for visualization of Peg trajectory under fluoroscopy prior to drilling.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”
Exit mobile version